MY206530A - Methods for treating neurodegenerative disorders - Google Patents
Methods for treating neurodegenerative disordersInfo
- Publication number
- MY206530A MY206530A MYPI2021000515A MYPI2021000515A MY206530A MY 206530 A MY206530 A MY 206530A MY PI2021000515 A MYPI2021000515 A MY PI2021000515A MY PI2021000515 A MYPI2021000515 A MY PI2021000515A MY 206530 A MY206530 A MY 206530A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- neurodegenerative disorders
- treating neurodegenerative
- treating
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713061P | 2018-08-01 | 2018-08-01 | |
| PCT/US2019/044023 WO2020028290A1 (en) | 2018-08-01 | 2019-07-30 | Methods for treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY206530A true MY206530A (en) | 2024-12-19 |
Family
ID=67614642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021000515A MY206530A (en) | 2018-08-01 | 2019-07-30 | Methods for treating neurodegenerative disorders |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12083082B2 (https=) |
| EP (1) | EP3829563B1 (https=) |
| JP (1) | JP7573512B2 (https=) |
| KR (1) | KR102716959B1 (https=) |
| CN (1) | CN112867485A (https=) |
| AU (1) | AU2019315853B2 (https=) |
| BR (1) | BR112021001739A2 (https=) |
| CL (1) | CL2021000269A1 (https=) |
| DK (1) | DK3829563T3 (https=) |
| EA (1) | EA202190406A1 (https=) |
| ES (1) | ES3011716T3 (https=) |
| FI (1) | FI3829563T3 (https=) |
| HR (1) | HRP20250206T1 (https=) |
| HU (1) | HUE070101T2 (https=) |
| IL (1) | IL280424B2 (https=) |
| LT (1) | LT3829563T (https=) |
| MX (1) | MX2021001287A (https=) |
| MY (1) | MY206530A (https=) |
| PH (1) | PH12021550213A1 (https=) |
| PL (1) | PL3829563T3 (https=) |
| PT (1) | PT3829563T (https=) |
| RS (1) | RS66516B1 (https=) |
| SG (1) | SG11202100767XA (https=) |
| SI (1) | SI3829563T1 (https=) |
| SM (1) | SMT202500080T1 (https=) |
| UA (1) | UA130011C2 (https=) |
| WO (1) | WO2020028290A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021025504A2 (pt) * | 2019-06-17 | 2022-04-26 | Alzheon Inc | Métodos para tratar distúrbios neurodegenerativos |
| MX2024007070A (es) * | 2021-12-09 | 2024-08-22 | Alzheon Inc | Alz-801 para uso en el tratamiento de la enfermedad de alzheimer. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| PT2089417E (pt) | 2006-10-12 | 2015-04-14 | Bhi Ltd Partnership | Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico |
| WO2013177367A2 (en) | 2012-05-23 | 2013-11-28 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
| WO2014121083A1 (en) | 2013-01-31 | 2014-08-07 | President And Fellows Of Harvard College | Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition |
| CA2941415A1 (en) * | 2014-03-21 | 2015-09-24 | Alzheon, Inc. | Methods for treating neurological disorders |
| FI3347002T3 (fi) | 2015-09-10 | 2023-08-10 | Alzheon Inc | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa |
-
2019
- 2019-07-30 JP JP2021505721A patent/JP7573512B2/ja active Active
- 2019-07-30 HU HUE19752795A patent/HUE070101T2/hu unknown
- 2019-07-30 SG SG11202100767XA patent/SG11202100767XA/en unknown
- 2019-07-30 FI FIEP19752795.5T patent/FI3829563T3/fi active
- 2019-07-30 CN CN201980064415.6A patent/CN112867485A/zh active Pending
- 2019-07-30 SM SM20250080T patent/SMT202500080T1/it unknown
- 2019-07-30 US US17/264,477 patent/US12083082B2/en active Active
- 2019-07-30 EA EA202190406A patent/EA202190406A1/ru unknown
- 2019-07-30 EP EP19752795.5A patent/EP3829563B1/en active Active
- 2019-07-30 BR BR112021001739-9A patent/BR112021001739A2/pt unknown
- 2019-07-30 RS RS20250164A patent/RS66516B1/sr unknown
- 2019-07-30 PT PT197527955T patent/PT3829563T/pt unknown
- 2019-07-30 AU AU2019315853A patent/AU2019315853B2/en active Active
- 2019-07-30 WO PCT/US2019/044023 patent/WO2020028290A1/en not_active Ceased
- 2019-07-30 IL IL280424A patent/IL280424B2/en unknown
- 2019-07-30 KR KR1020217005803A patent/KR102716959B1/ko active Active
- 2019-07-30 MY MYPI2021000515A patent/MY206530A/en unknown
- 2019-07-30 DK DK19752795.5T patent/DK3829563T3/da active
- 2019-07-30 LT LTEPPCT/US2019/044023T patent/LT3829563T/lt unknown
- 2019-07-30 ES ES19752795T patent/ES3011716T3/es active Active
- 2019-07-30 PL PL19752795.5T patent/PL3829563T3/pl unknown
- 2019-07-30 SI SI201930898T patent/SI3829563T1/sl unknown
- 2019-07-30 HR HRP20250206TT patent/HRP20250206T1/hr unknown
- 2019-07-30 MX MX2021001287A patent/MX2021001287A/es unknown
- 2019-07-30 UA UAA202101015A patent/UA130011C2/uk unknown
-
2021
- 2021-01-28 PH PH12021550213A patent/PH12021550213A1/en unknown
- 2021-02-01 CL CL2021000269A patent/CL2021000269A1/es unknown
-
2024
- 2024-08-02 US US18/793,452 patent/US20250213507A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3873604T (pt) | Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina | |
| ZA201906832B (en) | Novel psma-binding agents and uses thereof | |
| JOP20200041A1 (ar) | تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| TN2018000005A1 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| EA202092086A1 (ru) | Ингибиторы аргиназы | |
| PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| MY197631A (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| CR20210442A (es) | ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y (Divisional Exp. 2020-0214) | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| MX392158B (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| MX378940B (es) | Trastornos neurodegenerativos. | |
| ZA201901168B (en) | Novel compounds for treating parasitic disease | |
| DOP2020000006A (es) | Agentes, usos y métodos para el tratamiento | |
| MX378739B (es) | Compuestos de 2-oxindol. | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2021005502A (es) | Composiciones y metodos para tratar enfermedades neurodegenerativas. | |
| MA47595A (fr) | Méthodes de traitement d'affections neurodégénératives | |
| MY206530A (en) | Methods for treating neurodegenerative disorders | |
| ZA202006126B (en) | Compounds for treating alzheimer's disease | |
| WO2019136310A3 (en) | Novel compounds for the treatment of neurodegenerative diseases |